An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 01 Sep 2014
At a glance
- Drugs Carotuximab (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors TRACON Pharmaceuticals
- 28 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 06 May 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 20 May 2013 Results will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).